EAN 2020 | Alzheimer’s disease: what are the challenges when disease-modifying therapies become available?
Paola Barbarino
Paola Barbarino, CEO, Alzheimer’s Disease International, outlines the challenges to prepare healthcare systems for the diagnosis, treatment, and care of Alzheimer’s disease in a future with disease-modifying therapies. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).
Related videos
2:02
The role of phosphorylated tau in clinical trials
Elisabeth Thijssen
2:33
Using phosphorylated tau as a diagnostic tool for Alzheimer's disease
Elisabeth Thijssen
3:54
Repurposing existing drugs to treat Alzheimer's disease
Clive Ballard
3:26
Global guidelines for dementia risk reduction
Kaarin Anstey
3:34
Neurovascular dysfunction and Alzheimer's disease pathology
Costantino Iadecola
